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Abstract
Cancer stem cell is a progressive concept moving forward to interpret the hard-to-cure
nature of cancer and the relevant behavior in response to clinical therapies. Despite the
remaining debates regarding the existence of cancer stem cells, the cancer stem cell model
provides a potential approach for advanced innovative therapies targeting the “roots” of
cancer, which has enhanced treatment outcomes. This chapter summarizes advanced per‐
spectives in the field of cancer stem cell research, including experimental strategies for
targeting these cells, highlights challenges of this theory, and explores feasible therapeu‐
tic strategies for overcoming the intrinsic resistance of cancer stem cells to clinical treat‐
ment.
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1. Introduction
Cancer remains one of the leading causes of human death, and even though extraordinary
efforts and budget have been spent, clinical trials in the eradication or control of cancer
progression have generally created disappointing outcomes [1, 2]. Cancer develops originally
from normal cells through the accumulation of multiple genetic alterations that ultimately
convert to malignant phenotypes [3, 4]. Despite a better understanding of cancer biology and
evolutionary genomic characteristics, translating these achievements into feasible and
successful clinical outcomes continues to be a problem [5]. One attractive theory, the concept
of cancer stem cells (CSCs), being explored recently in cancer research may hold the answer
[6]. This chapter summarizes the major characteristics of CSCs and highlights several key
approaches used for CSC study, where they could be of help for efficient CSC-targeted therapy.
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
2. CSC: An involving concept moving forward
2.1. Cancer genetic evolution
Cancer biology and genomics have increasingly validated cancer as a complex adaptive
system. This landmark perspective was introduced by Peter Nowell in 1976, who viewed
cancer development as an evolutionary process driven by stepwise mutations with sequential,
subclonal selection at the nuclei acid level, a theory that is similar to Darwinian natural
selection [7]. This theory includes several key aspects. (1) Genetic instability: cells possess a
battery of mechanisms to preserve their DNA structural integrity. Cellular genetic structural
varies (deletions, duplications, and rearrangements) or DNA point mutations can initiate cell
biological changes that may lead to tumor formation. Thus, the perturbation of mechanisms
controlling genomic stability is responsible for the oncogenic processes [8]. (2) Error-prone
repair processes and a genotoxic exposure could result in particular mutational spectra of
cancer cells, including cigarette carcinogens, ultraviolet light, and chemotherapeutics. (3)
Recurrent, mutation specific traits in cancer can potentially affect clonal selection [9] (Figure 1).
Figure 1. Genetic diversification and clonal dynamics of cancer development.
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The microenvironment surrounding a tumor complexes with multiple cellular components
that provide an adaptive landscape and necessary elements for natural selection of cancer
growth [10]. The interaction between cancer cells and their surroundings is mutually beneficial
[11]. Cancer cells can reset the extracellular environment to be specialized niches for further
cancer growth and migration. The cancer niche in turn provides external signals for cancer-
clone expansion and tumor cell survival and proliferation. The spatial heterogeneity is critical
for evolving cancer cell to be a malignant phenotype and beneficial for cell migration and
distant invasion [12]. During the process of cancer-clone expansion, migrating cells invade
new habitats where they face new selective pressures, thereby increasing the rate of further
cancer mutation [13].
The cancer niche is an unclosed system. In addition to the tissue positions and associated
etiological environmental exposure of patients, the tissue microecosystem is manipulated by
multiple systemic or external factors [14]. Genotoxic exposures, such as ultraviolet light,
pathogenic infection, and long-term dietary habits, are able to modulate energy metabolism.
They are speculated to be the primary etiological causes of tumor initiation and further
evolution of cancer clones [14]. Cancer cell ecosystems can be altered following clinical
treatment, in which most cancer cells together with healthy tissues are killed under intensive
therapies. However, some specialized niches protect cells from cancer treatment, where variant
or therapy-resistant cancer cells emerge [15]. On the way of cancer progression and tumor
recurrence after therapy, the primary unit of selection is a specialized cell, known as CSC,
which possesses extensive self-renewal potential (Figure 2).
Figure 2. The cancer ecosystem.
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2.2. Cancer stem cell model
Cancer research was previously dominated by the clonal evolution model, also known as a
conventional stochastic model, a concept whereby all cells within a tumor have equal potential
to propagate and maintain a tumor following stepwise genetic and/or epigenetic changes, but
they are hard to identify the tumorigenic subset [7, 16–19]. Recently, accumulated studies
suggest cancers as hierarchical organizations, which is the basis of the hierarchical or CSC
model [20]. In the CSC model, only a small subset of cancer cells possesses the ability to self-
renew, differentiates, and reforms a tumor. CSCs, as “roots of cancer” operating in a hierarch‐
ical fashion, are defined by their abilities [20–24] (1) to form new tumors with high efficiency
that histologically resembles the original tumors when xenotransplanted into immunodefi‐
cient mice, (2) to generate descendant cells possessing unlimited self-renewal (regeneration)
potential but uncommitted differentiation options, and (3) to generate large populations of
differentiated offspring and progenitor cells that exit the stem cell state and lose the ability to
self-renew, thus no longer possessing tumorigenic potential. Such differentiated daughter cells
can undergo limited rounds of cell division because they lack the intrinsic clonogenic charac‐
teristics that are essential for tumor initiation and long-term progression of the malignancy.
The increasingly widespread attraction of the CSC model is due to the fact that it can provide
a plausible account for poorly understood clinical phenomena, such as therapy resistance, as
CSCs can resume growth and contribute to a new relapse after therapy suspension. It is critical
to appreciate that both the stochastic and CSC models share the same conviction that only a
small population of cancer cells are capable of maintaining cancer. The main difference is that
CSCs within the CSC model are characterized with the help of distinct cellular phenotypes [20].
Critically, the CSC model stands on the basis that CSCs are reliable and stable over time, and
their unique traits could not be obtained by differentiated descendants. It is worth to note that
the persuading of CSC model has been accompanying with intense debates amongst cancer
researchers. As evident from a new concept, the dynamic CSC model suggests that the CSC
phenotype is much more fluid than previously predicted and can be regulated by external
signals [25, 26]. Thus, not only can CSCs self-renew to create new progeny and differentiate to
non-CSCs but the de-differentiation of non-CSCs to CSCs can also occur and thus return to the
malignancy growth cycle [26–28]. This latest finding has significant implications for oncology
in that future effective anticancer therapeutic strategies should aim at targeting both CSCs and
non-CSCs (Figure 3).
Figure 3. Stochastic cancer model versus hierarchical and dynamic CSC models of tumor heterogeneity.
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3. Challenges and opportunities the CSC theory faces
Several challenges the CSC theory is now facing should be addressed before this concept can
fetch benefits for the clinically relevant entity [29].
3.1. Frequency of CSCs
One challenge that is intensely debated is how many CSCs exist within a tumor. Some studies
suggested that the frequency of CSCs is less than 1 in every 1000 cells in a tumor, which
supports the hierarchical status between CSCs and non-CSCs [30, 31]. However, recent
evidences reported that the number of cells that possess intrinsic tumorigenic potential is
relatively higher [32, 33]. Hepatocytes possess the potential of self-renewal and unlimited
proliferation under certain conditions [34, 35]. It is shown that various colorectal cancers do
not follow the same hierarchy as their CSC frequencies vary [36]. More importantly, the
prediction of the number of CSCs in a particular tumor type depends on multiple manual
factors, including the experimental procedure designed, the choice of cell surface markers, and
the types of immunodeficient mice into which the CSCs were injected. Chiba et al. used the
technique of side population (SP) analysis to detect the subpopulations that act CSC functions
and revealed that SP cells possess abilities of high proliferation and antiapoptosis in both Huh7
and PLC/PRF/5 cells with a percentage of 0.25% and 0.8%, respectively [37]. Kimura et al.
determined the frequency of CSCs by analyzing cell surface markers and the percentage of
CD133+ cells in Huh7 and PLC/PRF/5 were 2.7% and 23.5%, which is totally different with the
number obtained on the base of EpCAM-positive cells, with a proportion of 89.1% and 40.7%,
respectively [38]. However, Cao et al. found the CSC frequency of PLC/PRF/5 cells was 8.8%
by using the sphere-forming assay [39]. Thus, considering a tumor as a hierarchical malignancy
has intrinsic limitations, as a large population of cancer cells cooperate and contribute to tumor
growth, which is consistent with the conventional nonhierarchical model of malignancies [40].
3.2. Therapy resistance of CSCs
The failure of cancer initial treatment is normally explained due to the presence of a subset of
resistant cancer cells. CSCs are supposed to be one of such cells; they are logically resistant to
traditional chemotherapies owing to their “stem-like” features, including enhanced abilities
of DNA damage repair and cellular detoxification capacity via elevated aldehyde dehydro‐
genase (ALDH) activity, increased expression of enhancement of ATP-binding cassette (ABC)
surface transporters, and their nature quiescence [41–43]. CSCs with an up-regulation of
antiapoptotic molecules or a high expression of drug efflux pumps respond quite differently
when exposed to drugs; they can both survive after cancer treatment [44]. The rapid relapse
of the malignancy suggests that the clonogenic core of the cancer was not effectively targeted,
and this might be due to the de-differentiation of non-CSCs to CSCs [45]. Even though CSCs
are believed to be the most promising candidates for overcoming chemoresistance and tumor
recurrence, both CSCs and non-CSCs should be targeted eventually.
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3.3. Isolation of CSCs
The isolation and subsequent assessment of CSCs are clearly a rapidly developing area in
which diverse strategies were incorporated for obtaining higher CSC purities. One continual
concern after isolation assays is that whether the proposed CSCs separated from the bulk of
the tumor can still possess the intrinsic cellular properties. The selected CSCs require the
distinct phenotypes that can generate a similar malignancy to the parental tumor when
transplanted into immunodeficient mice [46]. The subsequent challenge is to optimize
experimental procedures to allow xenotransplantation of viable single suspension cells into
animals.
3.4. Targeting “confirmed” CSCs
Due to the relevance of cancer development, CSCs are ideal targets for molecular-directed
therapies. The limitation is that CSCs are typically present at very low levels. In addition, CSC
markers overlap with normal stem cells or between CSCs [47]. These drawbacks indicate that
the identification of CSC markers for guiding molecular therapeutics is still in its infancy. Many
CSC markers are not strictly CSC antigens since they present on normal cancer cells as well,
but they are molecules that support CSCs in their niche.
The characterization of CSCs has led to some experimentally “confirmed” markers or markers
involved in the process of targeting or interaction with CSCs. Epithelial cell adhesion molecule
(EpCAM) is one of the most highly expressed tumor-associated markers, being found in a
broad range of epithelial cancers. EpCAM has been “rediscovered” as a CSC antigen in breast,
colon, prostate, and pancreatic cancers [48–50]. In studies on colon cancer tumorigenicity,
EpCAMhighCD44+ was considered as a robust marker of more “stem-like” subpopulations.
Also, recruiting effector cells to tumors using an anti-EpCAM/anti-CD3 bispecific antibody
has been shown to be a promising strategy in the treatment of cancer [51].
In addition to cell-surface markers that are frequently utilized to identify CSCs, the high
activity of signal transduction routes can also contribute to CSCs features [52]. The self-renewal
capacity of CSCs leads to a long-term clonogenicity mutation, which might be effectively
therapeutically targeted. The activation of intracellular signaling pathways associated with the
self-renew of CSCs, including Wnt pathway, Hedgehog (Hh) pathway, and Notch pathway,
can stimulate a more immature tumor phenotype, facilitate tumor invasion, and promote
therapy resistance [53]. The interference of such pathways that promote CSC function might
provide an effective therapeutic window for drugs in the war against cancer. These stem cell-
associated surface marker proteins and pathways are promising targets for anticancer drug
development
4. Approaches used for studying CSCs
The primary challenge to study CSCs is the ability to identify and investigate CSCs in labora‐
tories using both in vitro and in vivo assays. This section addresses the methodologies that
have been widely used for isolation and characterization of CSCs.
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4.1. In vivo xenotransplantation and limiting dilution assay: The gold standard
Limiting dilution assays (LDAs) have been used in a broad variety of biological fields. LDA is
an experimental technique that attempts to quantify the frequency of biological particles that
perform a particular function within a larger mixed population [54]. The aim of LDA is to
obtain highly precise data at the macro level. To achieve this goal, several conditions must be
considered [55, 56]. First, the cells should be Poisson distributed. Second, the assay should be
designed with maximum information containing both negative and positive cultures. More‐
over, the conditions must be performed at the state that the response of a single limiting particle
can be detected. Thus, the culture conditions should be uniform in all paralleled groups and
wells [56].
The ability to determine the number of CSCs is a critical step for the success of in vivo
transplantation. However, there has been little or no attempt to standardize this approach [57].
In all conditions tested, the statistical behavior of the system (Es) and changes in condition
over time and statistical noise were the two major contributors to overall uncertainty [57].
However, as expected from statistical principles, Es declines with increasing number of
replicates analyzed. Also, increasing the number of replicates beyond 96 is unlikely to provide
substantial decreases in error, and fewer wells can be used to obtain results with similar
precision. Another requirement that arises in stem cell research is the need to accommodate
small numbers of replicates in a statistically consistent and defensible manner. Operator error,
mouse-to-mouse error, and other errors appear to play minor roles. These findings establish
parameters that contribute to the variability of LDA and provide strategies for the optimization
and interpretation of the LDA-based CSC estimates. To this end, extreme limiting dilution
analysis (ELDA) has emerged as the preferred method that is based on sound statistical
principle and methodologies [58]. ELDA works well when the number of replicates is small.
The CSC concept brings essential predictions of cancer research including susceptibility to
chemotherapy, aggressiveness of the disease, and the pace of recurrence that may largely be
influenced by the functional properties of CSCs [48, 49, 59–61]. To functionally measure CSC
potential, the operational assay of evaluating CSCs has been developed. The creation of an
array of genetically modified immunodeficient mice enabling analogous xenograft experi‐
ments can be used to determine and quantify cells that obtain tumor-initiating activity in
human tumors [48, 49, 59–61]. These xenograft models are considered the “gold standard” in
CSC research; they are able to guide the biology and therapeutic responses of human CSCs.
The enumeration of CSCs has been performed using phenotypic markers in in vitro limiting
dilution transplantation assays. Some key aspects should be considered [32]: (1) inefficient
engraftment in mice may result in underestimation of the actual CSC frequency; (2) phenotypic
characterization of CSCs may lead to different rates depending on the antibody combinations
used, and the use of specific antibodies may induce immune-mediated clearance of CSCs [48];
(3) the approach of tumor implantation (e.g., intravenously, intrafemorally) critically defines
engraftment and affects the export of stem cell frequency [62]; and (4) the kind of mouse strain
used as tumor recipient and the degree of mouse immunodeficiency are other factors need to
be considered [32]. It is reported that the use of adjuvants/culture supplementary (e.g., Matrigel
or growth factors) influences not only the measured frequency of CSCs but their phenotypes
as well [30, 32].
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4.2. The side population assay
In addition to the isolation and identification of CSCs through a set of cell surface markers
(such as CD44+/CD24low/lin-/ALDH+, CD44+/CD24low, EpCAM+/CD44+/CD24–, or CD34+/
CD38–). The SP discrimination assay is another flow cytometry method used to detect stem
cells based on the properties of the Hoechst dye efflux via the ABC transporters [63]. The SP
assay has been used to identify stem cell and progenitor populations in various tissues [64,
65]. However, several reports have stated that dye efflux is not a universal property of all stem
cells although SPs are much abundant within stem cells [66]. SPs are not just restricted to the
stem cell phenotypes as ABC transporters are also expressed by specialized cells in certain
organs [67]. The ABC transporters are believed to play a key role in those tissues, protecting
the cytotoxic effects of toxins [68]. However, the identification of CSCs has raised interests in
the SP assay, and SP subpopulations isolated from some cancers possess capabilities of drug-
resistant, self-renewal, and tumorigenicity when transplanted into immunocompromised
mice [63]. The SP assay can play an extremely valuable role in the primary isolation and
identification of potential stem/progenitor cells, when specific cell surface markers were
absent.
4.3. Clonal sphere formation assay and proliferation (invasion assay) assay
The clonal sphere formation assay is another functional method used for the identification of
CSCs and their purification from the rest of neighboring cells [69, 70]. This assay begins with
reliable single cell suspensions originating from primary tumors or established cancer cell
lines. Serial dilutions of the single cancer cell suspensions are seeded on ultra-low attachment
substrata in the presence of serum-free media with growth factors [71]. CSCs can grow into
3D nonadherent structures called spheres, while non-CSCs cannot survive in such culture
conditions. The results of the assay may become more reliable if the spheres are serially
passaged. The self-renewal capacity of sphere-generating cells can be estimated by evaluating
the sphere formation frequency through LDA and measuring sphere size [72]. The sphere
formation assay has been used to identify adult stem cells or CSCs from a number of tissues,
including mammary gland, brain, skin, and human melanoma [73–76].
4.4. Enzymatic assay of cell-surface markers
CSCs can be isolated by the enzymatic activities (ALDH activity) [77, 78]. The measurement
of ALDH activity by ALDEFLUOR staining is useful to screen tumor cells for resistance to
alkylating agents and to identify heterogeneity within tumor cells [79]. The ALDH+ population
is consistent with CSC characteristics, generating tumors that recapitulate the phenotypic
heterogeneity of the initial tumor. The measurement of ALDH populations revealed that the
ALDH+ cells were capable of self-renewing into both ALDH+ and ALDH− cells [80]. A recent
study in melanoma described both ALDH+ and ALDH− cells derived from patient biopsies
(100 or 2000 cells, respectively) were able to efficiently form tumors. It is also reported that
ALDH cells alone may not be sufficient for CSC selection [32]. Despite this, studies in breast
cancer combining other CSC surface markers with Aldefluor have improved tumorigenic
enrichment and this combination may prove to be a better strategy for enrichment of CSCs [32].
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4.5. Slow-cycling population assay
The slow-cycling population assay can be used to distinguish CSCs from progenitor cells,
which determines the incorporation of labeled precursor of nucleotides for cellular DNA
synthesis [81]. The slow-cycling cells, such as CSCs, maintaining sufficient labels allow their
detection by the anti-BrdU antibody staining or radioactive label [82]. Some technical issues
impede the accuracy of BrdU detection: (1) it is hard to demonstrate that cells have a similar
cycling in vitro and in vivo because of the destructive nature of the BrdU detection procedure,
(2) it is not expected that all the stem cells can be equally labeled because the BrdU incorpo‐
ration occurs only during the S phase of cell cycle, and (3) the label retention depends on the
length of the cell cycle, while the later status appears to alter as the organ matures [83]. Thus,
quantification of stem cells through this assay requires further confirmation through other
methods.
4.6. Lineage labeling assay
The lineage labeling assay was initially developed for understanding and tracing the biological
developments of a cell, including the identification of cell origin, measuring lineage relation‐
ships, and determination of division patterns [84]. In this assay, cells are labeled (usually with
a fluorescent dye or tag), followed by tracing in vitro and in vivo. There are several inherent
limitations with this technique: (1) the experimental procedure can damage cells or some cells
may have weak and/or transient expression of markers and unrestricted clonality [84] and (2)
with whole-mount labeling, it is not possible to identify spatial relationships between stem
cells and its transit amplifying progeny [85]. In this case, targeted cells are noninvasively
labeled in their native environment, and the development of a progenitor cell and a composi‐
tion of their lineages can be followed. It remains unclear whether the combination of these
techniques can be extended to identify CSCs and metastatic initiating stem/progenitor cells.
While there has been a hot debate in recent years as to whether the CSC theory is correct, very
recent lineage tracing studies have provided proof that a relatively small number of cells are
capable of generating and maintaining a tumor. These studies used fluorescently labeled tumor
cells and showed that the quiescent cells remained after further in vivo passages [86]. Fur‐
thermore, following treatment, these quiescent cells started to proliferate and generate
proliferative progenitor cells that were capable of maintaining a tumor [87–89]. By eliminating
these quiescent cells, tumor growth was impaired. These results link back to the theory that
leaving a small population of CSCs after the conventional treatment lead to a recurrence of the
tumor. Therefore, it is necessary to eliminate both populations of cells within a tumor to
produce effective anticancer therapeutic strategies [90].
4.7. CSC epigenome and next-generation sequencing
Whole genome sequencing has made tremendous contributions to cancer research, which
enables researchers to discover and understand the rules of cancer development at the nucleic
acid level [91, 92]. However, the genome instability and genetic variants limit to demonstrate
cancer progression. It was speculated that there exist a senior layer of information, besides
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genome sequence for regulating differential gene expressions and thus determining cancer
evolving. This concept was early prospected by Conrad Hal Waddington in 1942 and subse‐
quently described as “epigenetic control system” by Nanney in 1958 [93, 94]. Epigenetics
primarily refers to the study of chromosome variations that modulate gene transcription
without alterations in the DNA sequences [95, 96]. Epigenome contains genetic information,
not as stable as genome, representing the cellular epigenetic state varying with influence from
external factors. Mechanisms produce such changes mainly include DNA methylation, histone
modifications, nucleosome positioning, and chromatin remodeling [96]. These epigenetic
regulation mechanisms are reported to be closely related with the gaining of stem cell-specific
properties, whereby contributing to tumor inheterogeneous [97, 98]. Epigenetic alterations
would offer survival benefits in CSC subpopulation which promotes the genetic expression to
the self-renewal state, resulting in tumor initiation and further progression [99, 100]. The
relevance of the DNA methylation and histone modifications in CSC regulation, subsequently
with advancing tumor growth, were recently illustrated in various cancer models [97, 99, 101].
Next-generation sequencing (NGS), also known as high-throughput sequencing, has revolu‐
tionized the study of genomics and opened a new chapter of the epigenome research of cancer
and stem cell [102, 103]. Four mainly NGS-based approaches have been developed to identify
epigenome research, including methylated DNA immunoprecipitation sequencing (MeDIP-
Seq), whole genome bisulfite sequencing (WGBS), reduced representation bisulfite sequencing
(RRBS), and chromatin immunoprecipitation sequencing (ChIP-Seq). Compared with the
previous approach, the innovative advantages of NGS have significantly accelerated the
sequence of DNA and RNA and promoted the scientific sightings in CSC epigenome research.
5. Therapeutic strategies used for targeting CSCs
Current failure of cancer treatment is normally due to the existence and functionalities of CSCs,
which possess more chemoresistance than their non-CSC counterparts, to conventional
treatments. Recently, multiple strategies have been developed for targeting and eradicating
CSCs while sparing healthy tissues, thereby minimizing the patients to face therapy risks.
5.1. Targeting CSCs via surface markers
Since CSCs are attractive targets for anticancer treatment, the CSC-correlated cell surface
proteins have been monitored extensively for identification, probable isolation and monitoring
the variation of leukemic and solid CSCs in preclinical and clinical settings [104]. Studies using
certain ligands or antibodies against CSC surface maker proteins, including EpCAM, CD47,
CD44, CD90, CD133, IL-3R, immunoglobulin mucin TIM-3, ALDH+, and others, have ad‐
vanced the therapeutic efficacy [105–108]. Limitations, such as the expression of such cell
surface makers, may vary in different stages of cancer development; only a small subpopula‐
tion of CSCs standing in the summit among bunk of cancer cells, as well as overlapping of
CSC-associated marker proteins with normal stem cells, impede the effectively targeting of
CSCs [47]. For bench assays, it is recommended to employ functional studies such as in vivo
Smart Drug Delivery System126
LDA upon xenotransplantation to ascertain CSCs, rather than solely be dependent on the
incidence of a single or a combination of multiple CSC markers. However, in case of in vivo
CSC-based therapy, the CSC surface marker proteins present one of the very few feasible
options for targeting CSCs in animals and patients, given the practical and ethical restrictions
related with lineage tracing and xenotransplantation.
Accumulated attractions have been grasped in the development of aptamers (also known as
chemical antibodies) and monoclonal antibodies for targeting CSCs via targeting surface
marker proteins. Shigdar et al. have isolated two RNA aptamers using SELEX for targeting
CSC surface markers, EpCAM, and CD133 [109, 110]. These CSC-targeting aptamers internal‐
ize into target cells through receptor-mediated endocytosis, which is capable of circumventing
ATP-binding cassette transporters that function multiple drug resistance in CSCs [26]. In
addition, this newly developed EpCAM RNA aptamer is more sensitive than counterpart
antibodies for detecting the surface EpCAM proteins in formalin-fixed paraffin-embedded
primary breast cancers, with no nonspecific staining or cross-reactivity with non-EpCAM-
expression tissues [111]. This shows the potential of aptamers for specific targeting of cancers
but with minimized side effects observation. To optimize promising approaches by targeting
cell surface markers might be one of the answers for tracing CSCs and eventually eradiating
CSCs, thereby preventing patients from suffering from cancer attacking.
5.2. Targeting ATP-driven efflux transporters
The failure of cancer chemotherapy mainly results from increased efflux of anticancer drugs
from cancer cells, resulting in the impairment of drug cellular entrance and consequent
reduction of chemotherapeutic sensitivity [112]. A considerable root of multidrug resistance
(MDR) involves the augmented expression of the ABC transporter superfamily, many of these
transmembrane proteins are responsible for effluxion of various xenobiotics (including
anticancer agents) from cancer intracellular membranes [112, 113]. The well-characterized
MDR transporters consist with ABCB1 (MDR1 or P-glycoprotein), ABCC1 (MRP1), and
ABCG2 (BCRP or MXR) [112, 114–116]. Although projects focusing on understanding the
mechanisms of these ABC transporters behind chemotherapy failure have been broadly
developed, clinical outcomes in these fields have been generally unsatisfactory [113, 117]. The
recurrence of primary and metastatic cites can occur following the escaped chemotherapy, in
which CSCs, possessing enhanced efflux of therapeutic agents through ABC transporters, have
been proven to provide major contributions [114, 118, 119].
Due to the correlation of ABC transporters with CSC phenotypes, one approach circumventing
CSC-based chemoresistance involves the use of specific molecular inhibitors against certain
functions of individual MDR transporters [114]. Verapamil, an agent targeting general ABC
transporters, has been moved to the clinical trials, but the further study was suspended due
to the dose-limiting toxicity [120]. Thus, the more specific molecules targeting individual MDR
transporters are required [121]. A considerable body of evidence has shown positive outcomes
of overcoming CSC drug resistance by developing physical conjugation or chemical nanopar‐
ticle-functionalized drug delivery of anticancer agents. Chou et al. indicated that the conjuga‐
tion of doxorubicin (DOX) into nanodiamonds reduced efflux of DOX in MDR1 overexpressing
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cancer cells and facilitated the anticancer efficacy in DOX-resistant cancer models [122]. While
CSC-related chemoresistance and tumor relapse arise mainly due to the increased expression
of ABC transporters, the therapeutic strategies developed for specifically disturbing actions of
ABC transporter proteins would be an attractive potential for targeting and eradicating CSCs.
6. Conclusions
The CSC concept is still an evolving model moving forward. Recent lineage tracing strategy
has proven the existence and functions of CSCs in progression of solid tumors. CSCs with
intrinsic activities of chemoresistance are the culprit in tumor recurrence and the root of
treatment failures. Challenges remain on how to efficiently identify and target CSCs in vivo
and monitor CSCs posttreatment. Cancer biology has proofed that traditional clonal evolution,
and CSC models are not exclusive but co-exist with each other in tumorigenesis. Therefore,
future elucidation of molecular mechanisms underlying CSC biology should open a new
window of efficacious novel therapy strategies that eliminate both CSCs and non-CSCs.
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